Condition: Von Willebrand Disease (VWD) · Sponsor: Shanghai RAAS Blood Products Co., Ltd.
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in patients with von Willebrand disease.
This description comes directly from the study's public registry record.
Research and Development · 862122130888 · hanyu@raas-corp.com
Always discuss trial participation with your own doctor first.
| Xiangya Hospital of Central South University | Changsha, China | Recruiting |
| The First Affiliated Hospital of University of Science and Technology of China | Hefei, China | Recruiting |
| Jinan Central Hospital | Jinan, China | Recruiting |
| The First Affiliated Hospital of Guangxi Medical University | Nanning, China | Recruiting |
| The First Affiliated Hospital of Soochow University | Suzhou, China | Recruiting |
| The Second Hospital of Shanxi Medical University | Taiyuan, China | Recruiting |
| North China University of Science and Technology Affiliated Hospital | Tangshan, China | Recruiting |
| Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences | Tianjin, China | Recruiting |
| Henan Provincial People's Hospital | Zhengzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07640893